中西医结合治疗慢性阻塞性肺疾病急性加重期的临床观察

In tegrated Traditional Chinese and Western Medicine on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的观察中西医结合对慢性阻塞性肺疾病急性加重期的疗效并探讨其机制。方法对照组给予西药对症治疗,观察组在对照组的基础上加用痰热清注射液及清热化痰活血降气方剂。结果治疗后观察组总有效率为93.75%,明显高于对照组的75.00%(P<0.05);治疗后观察组CAT评分及咳嗽、痰量、气喘症状体征积分均较对照组明显下降(P<0.05);治疗后两组FEV1、FEV1%、FEV1/FVC均较前改善(P<0.05),且治疗组的FEV1、FEV1%、FEV1/FVC改善程度较对照组更显著(P<0.05)。治疗后两组FIB、CRP及PCO_2均较治疗前明显下降(P<0.05),观察组FIB、CRP及PCO_2较对照组有明显下降(P<0.05);治疗后两组PO_2明显上升(P<0.05),观察组PO_2较对照组上升明显(P<0.05)。结论中西医结合治疗能更好地改善AECOPD患者的临床症状及生活质量、肺功能水平、炎症水平和高凝状态。

Objective： To explore the curative effect of integrated traditional Chinese and Western Medicine on acute exacerbation of chronic obstructive pulmonary disease. Methods： The control group was given symptomatic treatment,and the observation group was treated with Tanreqing injection and Chinese medicine of removing heatphlegm,invigorating the circulation of blood and sending down abnormally ascending. Results： After treatment,the total effective rate of the observation group was 93.75%,and that of the control group was 75.00%. The difference between the two groups was statistically significant（P 0.05）. After treatment,the scores of CAT,cough,sputum,asthma and other symptoms and signs in the observation group were significantly lower than those in the control group（P 0.05）. After treatment,FEV1,FEV1% and FEV1/FVC of both groups were improved（P 0.05）,and the improvement of the observation group was more significant,compared with that of the control group. After treatment,FIB,CRP and PCO_2 in both groups were evidently decreased compared with before treatment（P 0.05）.FIB,CRP and PCO_2 of the observation group were obviously decreased compared with the control group（P 0.05）.After treatment,PO_2 of both groups were significantly higher（P 0.05）,and the observation group＇s PO_2 increased significantly compared with that of the control group（P 0.05）. Conclusion： The combination of traditional Chinese medicine and Western medicine can better improve the clinical symptoms,quality of life,pulmonary function,inflammatory level and hypercoagulability in patients with AECOPD.